Eltrombopag
- PDF / 170,642 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 75 Downloads / 141 Views
1
S
Various toxicities: 25 case reports In a retrospective study (between 2011 and 2017) involving 285 patients, 25 patients including 10 women and 7 men aged 18–82 years [not all ages and sexes stated] were described, who exhibited arterial thrombosis, venous thrombosis, hair loss, frequent pneumonia, maculation, frequent tonsillitis, thrombocytosis, erythrocytosis, ileus or diarrhoea while receiving eltrombopag for chronic immune thrombocytopenia. The patients, who had chronic immune thrombocytopenia, started receiving eltrombopag 50mg daily [route not stated]. Following 2–65 weeks of treatment, 17 of the 25 patients developed side-effects in the form of arterial thrombosis (5 patients) and venous thrombosis (12 patients). Of these 17 patients, five patients developed arterial thrombosis in the form of transient ischaemic attack (2 patients), myocardial infarction (1 patient), cerebrovascular accident (1 patient) and thrombosis with unspecified cardiac event leading to sudden death (1 patient); while the remaining 12 patients developed venous thrombosis in the form of deep vein thrombosis (9 patients), deep vein thrombosis and pulmonary embolism (2 patients) and pulmonary embolism (1 patient). The remaining eight of the 25 patients developed side-effects in the form of hair loss (1 patient), frequent pneumonia (1 patient), maculation (1 patient), frequent tonsillitis (1 patient), thrombocytosis (1 patient), erythrocytosis (1 patient), ileus (1 patient) and diarrhoea [1 patient; not all duration of treatment to reactions onsets stated]. Eltrombopag was discontinued in patients who developed thrombosis. The patients, who developed deep vein thrombosis, pulmonary embolism or myocardial infarction, were managed with unspecified anticoagulation treatment or anticoagulation tPA. The patients, who developed transient ischaemic attack, were managed with unspecified antiaggregation treatment. The patient, who developed cerebrovascular accident, was managed with unspecified antiaggregation treatment and unspecified anticoagulation treatment [not all outcomes stated]. Author comment: "The most common side effects were. . .venous thrombosis (4.2%), and arterial thrombosis (1.7%)". "Other side effects observed in only one patient each were as follows: hair loss, maculation, thrombocytosis, erythrocytosis, frequent tonsillitis, frequent pneumonia, diarrhea, and ileus." Cekdemir D, et al. A multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: A real-life experience. Turkish Journal of Hematology 36: 230-237, No. 4, Nov 2019. Available from: URL: http://doi.org/10.4274/tjh.galenos.2019.2018.0307 803443323 Turkey
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
